Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
38.5
USD
+1.34%
+3.08%
+90.12%
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Tarsus' Fourth Qu...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating
05-09
MT
Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, vs. Street Est of $17.9M
05-08
MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals
04-24
MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
04-24
AN
Tarsus Pharmaceuticals, Inc. Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-Dilutive Financing Commitment from Pharmakon
04-23
CI
Tarsus Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding
04-18
CI
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc
03-27
CI
Transcript : Tarsus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM
03-12
Tarsus Pharmaceuticals Prices $100 Million Public Offering
03-01
MT
Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating
02-29
MT
Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating
02-28
MT
Tarsus Pharmaceuticals' Q4 Net Loss Widens, Revenue Increases
02-27
MT
Transcript : Tarsus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
02-27
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q4 Revenue $13.1M, vs. Street Est of $5.9M
02-27
MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-27
CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-27
CI
Tarsus Announces Positive Topline Results from Carpo, A Phase 2A Proof-Of-Concept ?Tick-Kill? Trial Evaluating Tp-05 for the Prevention of Lyme Disease
02-22
CI
Tarsus Pharmaceuticals, Inc. Announces Executive Changes
01-18
CI
Tarsus Pharmaceuticals Insider Sold Shares Worth $810,623, According to a Recent SEC Filing
12-22
MT
Tarsus Pharmaceuticals Says Phase 2a Trial of TP-03 in Meibomian Gland Disease Yields Positive Results
12-11
MT
Tarsus Pharmaceuticals, Inc. Announces Positive Topline Results from the Ersa Phase 2A Clinical Trial Evaluating Tp-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
12-11
CI
Tarsus Pharmaceuticals Insider Sold Shares Worth $136,286, According to a Recent SEC Filing
12-01
MT
Tarsus Pharmaceuticals Insider Sold Shares Worth $136,270, According to a Recent SEC Filing
12-01
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Companyâs lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
More about the company
Last Close Price
38.5
USD
Average target price
55.78
USD
Spread / Average Target
+44.88%
Consensus
1st Jan change
Capi.
+90.12% 1.45B +35.01% 709B +30.98% 595B -2.60% 367B +20.83% 334B +5.69% 289B +14.38% 239B +9.20% 211B -3.48% 203B +10.77% 171B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**